[go: up one dir, main page]

ATE245699T1 - Rekombinant pgp3, verfahren zu dessen herstellung,und dessen verwendung in der diagnose und therapie - Google Patents

Rekombinant pgp3, verfahren zu dessen herstellung,und dessen verwendung in der diagnose und therapie

Info

Publication number
ATE245699T1
ATE245699T1 AT95915295T AT95915295T ATE245699T1 AT E245699 T1 ATE245699 T1 AT E245699T1 AT 95915295 T AT95915295 T AT 95915295T AT 95915295 T AT95915295 T AT 95915295T AT E245699 T1 ATE245699 T1 AT E245699T1
Authority
AT
Austria
Prior art keywords
diagnosis
therapy
production
pgp3
recombinant
Prior art date
Application number
AT95915295T
Other languages
English (en)
Inventor
Giulio Ratti
Original Assignee
Chiron Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Spa filed Critical Chiron Spa
Application granted granted Critical
Publication of ATE245699T1 publication Critical patent/ATE245699T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT95915295T 1994-04-19 1995-04-18 Rekombinant pgp3, verfahren zu dessen herstellung,und dessen verwendung in der diagnose und therapie ATE245699T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/229,980 US5629167A (en) 1994-04-19 1994-04-19 Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
PCT/IB1995/000310 WO1995028487A2 (en) 1994-04-19 1995-04-18 Recombinant pgp3, methods of preparation and use in diagnosis and therapy

Publications (1)

Publication Number Publication Date
ATE245699T1 true ATE245699T1 (de) 2003-08-15

Family

ID=22863480

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95915295T ATE245699T1 (de) 1994-04-19 1995-04-18 Rekombinant pgp3, verfahren zu dessen herstellung,und dessen verwendung in der diagnose und therapie

Country Status (8)

Country Link
US (5) US5629167A (de)
EP (1) EP0756630B1 (de)
JP (1) JPH10503922A (de)
AT (1) ATE245699T1 (de)
AU (1) AU2222795A (de)
CA (1) CA2188316A1 (de)
DE (1) DE69531345T2 (de)
WO (1) WO1995028487A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629167A (en) * 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
US5944670A (en) * 1996-12-02 1999-08-31 Oridion Medical Ltd. Breath test for the diagnosis of bacterial infection
US7459524B1 (en) * 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
PT1042001E (pt) * 1997-12-16 2002-09-30 Chiron Corp Uso de microparticulas combinadas com emulsoes submicronicas oleo-em-agua
US7393630B2 (en) * 1997-12-16 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Use of microparticles combined with submicron oil-in-water emulsions
EP1135501A1 (de) * 1998-12-01 2001-09-26 Aventis Pasteur Limited Chlamydia antigene, dafür kodierende dna und deren verwendung
ATE318924T1 (de) * 1998-12-04 2006-03-15 Univ Manitoba Zwei-schritte-verfahren zur impfung gegen chlamydia
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
GB9828000D0 (en) * 1998-12-18 1999-02-10 Chiron Spa Antigens
US6919187B2 (en) * 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
EP1463520B1 (de) 2001-12-12 2008-09-03 Novartis Vaccines and Diagnostics S.r.l. Immunisierung gegen chlamydia tracheomatis
WO2003089935A1 (en) * 2002-04-19 2003-10-30 Regen Biotech, Inc. THE METHOD FOR MEASURING THE AMOUNT OF βiG-H3 PROTEIN AND DIAGNOSTIC KIT USING THE SAME
DE10238825A1 (de) * 2002-08-23 2004-03-11 Roche Diagnostics Gmbh Mikrofluidische Systeme mit hohem Aspektverhältnis
USD508479S1 (en) * 2004-07-21 2005-08-16 Matsushita Electric Industrial Co., Ltd. Earphone with microphone
EP2152303A4 (de) * 2007-05-01 2011-10-05 Univ Texas Chlamydien-antigene als reagentien zur diagnose und behandlung von chlamydien-infektion und erkrankung
AU2009302821A1 (en) 2008-10-09 2010-04-15 Board Of Regents, University Of Texas System Methods and compositions for chlamydial antigens for diagnosis and treatment of chlamydial infection and disease
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
EP2544715A2 (de) * 2010-03-09 2013-01-16 Board Of Regents, University Of Texas System Verfahren und zusammensetzung für chlamydia-antigen zur diagnose und behandlung einer chlamydieninfektion und -erkranung
US10258682B2 (en) 2013-01-16 2019-04-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Attenuated chlamydia vaccine
CN105126077A (zh) * 2015-09-30 2015-12-09 侯淑萍 衣原体蛋白Pgp3在制备抑制银屑病样皮损药物中的应用
US11230576B2 (en) * 2016-08-11 2022-01-25 Navigo Proteins Gmbh Alkaline stable immunoglobulin-binding proteins
KR20200035112A (ko) 2017-08-07 2020-04-01 리플리겐 코포레이션 C-말단 나선형 영역에 시스테인을 갖는 fc 결합 단백질
CN112345768B (zh) * 2020-10-26 2021-05-07 华中农业大学 一种基于重组蛋白rsPgp3的家畜衣原体抗体的间接ELISA检测方法及试剂盒

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4336336A (en) 1979-01-12 1982-06-22 President And Fellows Of Harvard College Fused gene and method of making and using same
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
AU545912B2 (en) 1980-03-10 1985-08-08 Cetus Corporation Cloned heterologous jive products in bacillies
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
US4880911A (en) * 1982-03-19 1989-11-14 G. D. Searle & Co. Fused polypeptides and methods for their detection
US4876197A (en) 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
CA1341302C (en) * 1983-02-22 2001-10-09 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis of foreign protein
JPS59166086A (ja) 1983-03-09 1984-09-19 Teruhiko Beppu 新規な発現型プラスミドとそれらを用いて仔牛プロキモシン遺伝子を大腸菌内で発現させる方法
US4546083A (en) 1983-04-22 1985-10-08 Stolle Research & Development Corporation Method and device for cell culture growth
US4588684A (en) 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
ATE78293T1 (de) 1983-05-27 1992-08-15 Texas A & M Univ Sys Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors.
US4689406A (en) 1983-08-10 1987-08-25 Amgen Enhancement of microbial expression of polypeptides
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
JPS6054685A (ja) 1983-09-02 1985-03-29 Suntory Ltd 改良発現ベクタ−およびその利用
EP0136907A3 (de) 1983-10-03 1986-12-30 Genentech, Inc. Xenogeneisches Expressionskontrollsystem, Verfahren zu dessen Verwendung, dieses enthaltende Expressionsvektoren, mit denselben transformierte Zellen und daraus hergestellte heterolose Proteine
DK518384A (da) 1984-01-31 1985-07-01 Idaho Res Found Vektor til fremstilling af et gen-produkt i insektceller, fremgangsmaade til dens fremstilling samt dens anvendelse
US4880734A (en) 1984-05-11 1989-11-14 Chiron Corporation Eukaryotic regulatable transcription
DE3587759T2 (de) 1984-05-11 1994-07-07 Chiron Corp., Emeryville, Calif. Erhöhte Hefetranskription unter Verwendung einer Hybridkonstruktion der Promotorregion.
US4738921A (en) 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
US4745056A (en) 1984-10-23 1988-05-17 Biotechnica International, Inc. Streptomyces secretion vector
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
ATE63757T1 (de) 1985-03-28 1991-06-15 Chiron Corp Expression durch verwendung von fusionsgenen fuer proteinproduktion.
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4865974A (en) 1985-09-20 1989-09-12 Cetus Corporation Bacterial methionine N-terminal peptidase
JPS6296086A (ja) * 1985-10-21 1987-05-02 Agency Of Ind Science & Technol 複合プラスミド
ES2061482T3 (es) 1986-05-02 1994-12-16 Gist Brocades Nv Metodo para la identificacion de secuencias de señal secretora para sintesis de proteina extracelular en bacillus.
JPS63123383A (ja) 1986-11-11 1988-05-27 Mitsubishi Kasei Corp ハイブリツドプロモ−タ−、発現調節ｄｎａ配列および発現ベクタ−
DK175243B1 (da) * 1987-03-23 2004-07-19 Zymogenetics Inc Ekspressionsvektor, der er i stand til at styre ekspression af heterologe gener eller cDNA i gær, gærværtscelle samt fremgangsmåde til öget produktion af proteiner i gærværtsceller
GB8709746D0 (en) * 1987-04-24 1987-05-28 Wenman W M Chlamydia vaccine
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US4800734A (en) 1987-11-02 1989-01-31 White Consolidated Industries, Inc. Room air conditioner
CA1340772C (en) * 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US4973551A (en) * 1988-01-15 1990-11-27 Merck & Co., Inc. Vector for the expression of fusion proteins and protein immunogens
IT1224253B (it) * 1988-04-08 1990-09-26 Sclavo Spa Oligonucleotidi sintetici utili per la determinazione di chlamydia trachomatis in un campione biologico
HU212924B (en) * 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2659578B1 (fr) * 1990-03-14 1995-04-28 Peugeot Appareil d'alimentation automatique en flans de tole d'une presse ou autre machine quelconque.
US6248563B1 (en) * 1991-02-07 2001-06-19 Scalvo Spa Chlamydia trachomatis serotype D genes
IT1244706B (it) * 1991-02-07 1994-08-08 Sclavo Spa Plasmide pctd isolato da chlamydia trachomatis serotipo d, suoi geni e proteine da essi codificate; plasmidi ricombinanti per l'espressionedi detti geni in sistemi eterologhi come proteine ricombinanti di fusione, preparazione di dette proteine ricombinanti e loro uso nella formulazione di vaccini e/o diagnostici
US5629167A (en) * 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
US6448234B1 (en) * 1998-12-08 2002-09-10 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
DE60133190T2 (de) * 2000-04-21 2009-04-02 CORIXA CORP., Wilmington Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
US6919187B2 (en) * 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
EP1463520B1 (de) * 2001-12-12 2008-09-03 Novartis Vaccines and Diagnostics S.r.l. Immunisierung gegen chlamydia tracheomatis
US7105171B2 (en) * 2002-03-07 2006-09-12 The Regents Of The University Of California Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia

Also Published As

Publication number Publication date
AU2222795A (en) 1995-11-10
US7070791B2 (en) 2006-07-04
DE69531345T2 (de) 2004-04-15
US7485313B2 (en) 2009-02-03
WO1995028487A2 (en) 1995-10-26
DE69531345D1 (de) 2003-08-28
US5629167A (en) 1997-05-13
EP0756630A1 (de) 1997-02-05
US6210968B1 (en) 2001-04-03
WO1995028487A3 (en) 1995-12-28
CA2188316A1 (en) 1995-10-26
JPH10503922A (ja) 1998-04-14
US6649374B1 (en) 2003-11-18
EP0756630B1 (de) 2003-07-23
US20060147474A1 (en) 2006-07-06
US20040053393A1 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
ATE245699T1 (de) Rekombinant pgp3, verfahren zu dessen herstellung,und dessen verwendung in der diagnose und therapie
DK0868519T3 (da) Diagnose og behandling af AUR-1- og/eller AUR-2-relaterede lidelser
NL300009I1 (nl) Fusie-eiwitten met immuunglobulinedelen, hun bereiding en hun gebruik.
WO1989003846A3 (en) Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
AU6303490A (en) Novel hydrophilic derivatives, their application to diagnosis and to therapeutics, diagnostic or therapeutic kits and immunological reagents
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
SE8701905L (sv) Foerfarande och kit foer diagnos av iga-nefropati
ES557072A0 (es) Procedimiento para la obtencion de lineas celulares de hibridoma
ATE265533T1 (de) Saeugetierchemokine
DE69713146D1 (de) Helicobacter pylori diagnostika
EP0230934A3 (de) Monoklonaler Antikörper, Verfahren zur Messung eines glucosylierten Proteins unter Verwendung von diesem monoklonalen Antikörper, und Kit dafür
EP0585960A3 (de) Diagnostisches Verfahren für Autoimmunkrankenheiten
NO174110C (no) Monoklonalt antistoff til anvendelse in vitro for diagnose av maligne tumor- eller akutte inflammasjonssykdommer, og som er spesifikt for N-acetyl-neuraminsyre i hybridom som produserer antistoffet
ATE294237T1 (de) S?ugetier thymokingene
DE3886545D1 (de) Monoklonale human-antikörper, spezifisch für rh(d).
ATE73463T1 (de) Monoklonale antikoerper.
EP0112299A3 (de) Verfahren zur Reinigung von Superoxid-Dismutase mittels Affinitätschromatographie
EP0676468A3 (de) Humane T-Zellrezeptoren zur diagnostischen sowie therapeutischen Verwendung bei autoimmunem Diabetes mellitus
SE9501782D0 (sv) Method of predicting the therapeutic response of a drug against a malignant tumour
DK0789716T3 (da) Antistoffer mod allogene og xenogene proteiner, deres anvendelse ved diagnose og terapi og fremgangsmåder til bestemmelse h
DE69316911D1 (de) Reine tsh zubereitung, verfahren zur herstellung und ihre anwendung für die herstellung von tsh spürelementen für tsh rezeptor nachweis und in tsh rezeptor testproben
WO1994010205A1 (en) Protein specific for alzheimer's disease and method of diagnosing alzheimer's disease through detection of the protein
DE3821686A1 (de) Lektine als diagnostikum und deren einsatz fuer diagnostische verfahren zum nachweis von onkogenen rna-viren, oder deren bestandteile
DE3940009A1 (de) Mannose-spezifische lektine als diagnostikum und deren einsatz fuer diagnostische verfahren zum nachweis von onkogenen rna-viren oder bestandteilen von diesen
DE3787220D1 (de) Monoklonaler Antikörper gegen menschliches Plasminogen, Verfahren zu seiner Herstellung, diesen Antikörper enthaltendes Testreagenz sowie Testsatz und diesen Antikörper produzierendes Hybridoma.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0756630

Country of ref document: EP